Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > The Spirit Molecule (DMT)

<< Previous

Bullboard Posts

Next >>

Comment by nodaytraderon Jan 12, 2022 10:43am

124 Views

Post# 34307956

RE:RE:RE:RE:RE:The Spirit Molecule (DMT)

As I understand it, Algernon was never intended to be a production company but one that will sell or license use of repurposed drugs.
So It is setting out its stall and on that stall are;

Ifenprodil for chronic cough
Ifenprodil for IPF
Ifenprodil for Pancreatic Cancer
Ifenprodil for Small Cell Lung Cancet (Orphan Drug)
DMT as part of stroke rehabilitation therapy
DMT as possible treatment for acute stroke

if DMT is to be the major focus, its development might be financed by use of Ifenprodil

It will be very interesting to see what NASDAQ investors think of the display.

<< Previous

Bullboard Posts

Next >>

Thesis Gold makes high-grade discovery at Ring Zone